| Drug Name |
Necitumumab |
| Drug ID |
BADD_D01543 |
| Description |
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). |
| Indications and Usage |
Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01FE03 |
| DrugBank ID |
DB09559
|
| KEGG ID |
D10018
|
| MeSH ID |
C527969
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D03WPP
|
| NDC Product Code |
0002-7716; 0002-2412; 73424-0547 |
| UNII |
2BT4C47RUI
|
| Synonyms |
necitumumab | Portrazza | IMC-11F8 | 11F8 | IMC-11F8 monoclonal antibody |
